Phase II study of antineoplastons A10 and AS2-1 in patients with multiple myeloma
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 26 Oct 2008 Planned end date changed from 1 Jan 2008 to 1 Dec 2000 as reported by ClinicalTrials.gov.
- 18 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.